Drug Profile
RTX 134
Alternative Names: RTX-134Latest Information Update: 11 Aug 2023
Price :
$50
*
At a glance
- Originator Rubius Therapeutics
- Developer Rubius Therapeutics [CEASED]
- Class Cell therapies; Gene therapies
- Mechanism of Action Phenylalanine ammonia lyase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Phenylketonuria
Most Recent Events
- 31 Dec 2022 Discontinued - Phase-I for Phenylketonuria in USA (IV) (Rubius Therapeutics website, December 2022)
- 01 Dec 2022 Rubius Therapeutics terminates a phase I trial in Phenylketonuria in USA (IV) due to Sponsor decision (NCT04110496)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Phenylketonuria in USA (IV, Infusion)